Content area
Full text
Themis Bioscience has postponed its planned IPO in Amsterdam. The Austrian biotech is now looking into “all strategic options” to secure the cash it needs to move its chikungunya vaccine into phase 3.
Themis outlined plans to list its stock in the Netherlands in the middle of last month and set a price range for an anticipated €40 million ($45 million) offering two weeks later. Biotech stocks have been on a wild ride since Themis first revealed its plans, causing the Nasdaq Biotechnology index to fall by as much 9%...